News
NRXBF
0.392
NaN%
--
Weekly Report: what happened at NRXBF last week (0706-0710)?
Weekly Report · 6d ago
NurExone closes C$ 627,795 non-brokered private placement of 1,012,573 units at C$ 0.62 each
PUBT · 07/07 07:50
Weekly Report: what happened at NRXBF last week (0629-0703)?
Weekly Report · 07/06 10:29
NurExone closes non-brokered private placement raising C$ 627,795.26
PUBT · 06/30 12:32
NurExone Announces Closing of Non-Brokered Private Placement
Barchart · 06/30 07:31
Weekly Report: what happened at NRXBF last week (0622-0626)?
Weekly Report · 06/29 10:24
NurExone unit Exo-Top signs binding MOU for Mexico distribution of naive exosome products
PUBT · 06/24 21:18
NurExone unit Exo-Top signs MOU with ExoLyra for exclusive Mexico distribution of naive exosomes
PUBT · 06/24 21:01
EXO-TOP, NUREXONE’S WHOLLY OWNED U.S. SUBSIDIARY, ENTERS INTO BINDING MOU FOR NAÏVE EXOSOME DISTRIBUTION IN MEXICO
Reuters · 06/24 21:01
EXCLUSIVE: France Based NurExone Targets Mexico Wellness Market With Exosome Supply Agreement
Benzinga · 06/24 20:31
EXCLUSIVE: NurExone's Wholly-Owned Subsidiary Enters Into Binding MOU For Naïve Exosome Distribution in Mexico
Benzinga · 06/24 20:30
Weekly Report: what happened at NRXBF last week (0615-0619)?
Weekly Report · 06/22 10:34
Weekly Report: what happened at NRXBF last week (0608-0612)?
Weekly Report · 06/15 10:34
NurExone wins South Korea patent for ExoPTEN exosome therapy platform
PUBT · 06/14 06:15
Weekly Report: what happened at NRXBF last week (0601-0605)?
Weekly Report · 06/08 10:29
NurExone Biologic publishes Q1 FY2026 MD&A for three months ended March 31, 2026
PUBT · 06/01 13:49
NurExone Q1 FY26 net loss widens to US$1.77 million
PUBT · 06/01 12:10
Weekly Report: what happened at NRXBF last week (0525-0529)?
Weekly Report · 06/01 10:35
NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update
Barchart · 06/01 07:02
Weekly Report: what happened at NRXBF last week (0518-0522)?
Weekly Report · 05/25 10:39
More
Webull provides a variety of real-time NRXBF stock news. You can receive the latest news about Nurexone Biologic Inc through multiple platforms. This information may help you make smarter investment decisions.
About NRXBF
Nurexone Biologic Inc is an Israel-based company engaged primarily in the pharmaceutical sector. The Company is engaged in developing a platform for biologically guided exosome-based therapies to be delivered, minimally invasive, to patients who have suffered central nervous system injuries. The Company’s flagship product, ExoPTEN for acute spinal cord injury, uses exosomes loaded with a specific and sIRNA sequence as the active pharmaceutical ingredient. Its ExoTherapy is a platform for developing exosome-based therapies. The NurExone platform technology is expected to offer solutions to drug companies interested in minimally invasive targeted drug delivery for other indications. The Company focuses on research and development of pharmaceutical technologies.